

Insulin Like Growth Factor I - Pipeline Review, H2 2020

<https://marketpublishers.com/r/I225D13A94E5EN.html>

Date: November 2020

Pages: 52

Price: US\$ 3,500.00 (Single User License)

ID: I225D13A94E5EN

Abstracts

Insulin Like Growth Factor I - Pipeline Review, H2 2020

SUMMARY

Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) - Insulin-like growth factor 1 (IGF-1) also called somatomedin C is a protein encoded by the IGF1 gene. It stimulates glucose transport in bone-derived osteoblastic (PyMS) cells and is effective at much lower concentrations than insulin. It plays a role in synapse maturation. It acts as a ligand for IGF1R. It binds to the alpha subunit of IGF1R, leading to the activation of the intrinsic tyrosine kinase activity which autophosphorylates tyrosine residues in the beta subunit thus initiates a cascade of down-stream signaling events leading to activation of the PI3K-AKT/PKB and the Ras-MAPK pathways. It binds to integrins ITGAV: ITGB3 and ITGA6:ITGB4. It also binds to integrins and subsequent ternary complex formation with integrins and IGFR1 are essential for IGF1 signaling.

Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) pipeline Target constitutes close to 9 molecules. Out of which approximately 5 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Preclinical and Discovery stages are 2, 2 and 1 respectively. Similarly, the universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 1 and 2 molecules, respectively. Report covers products from therapy areas Oncology, Cardiovascular, Central Nervous System and Metabolic Disorders which include indications Acute Ischemic Stroke, Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Breast Cancer, Cerebral Infarction (Brain Infarction), Huntington Disease, Metastatic Breast Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Multiple Sclerosis, Neuroendocrine Tumors, Neuropathic Pain (Neuralgia), Non-Small Cell Lung Cancer, Peripheral Nerve Injury, Prostate Cancer, Solid Tumor and Type 1 Diabetes (Juvenile

Diabetes).

The latest report Insulin Like Growth Factor I - Pipeline Review, H2 2020, outlays comprehensive information on the Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1)

The report reviews Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) targeted therapeutics and enlists all their major and minor projects

The report assesses Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) -
Overview

Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) -
Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) -
Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) -
Companies Involved in Therapeutics Development

Boehringer Ingelheim International GmbH

Genervon Biopharmaceuticals LLC

Kriya Therapeutics Inc

Regulaxis SAS

Stem Cell Medicine Ltd

Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) -
Drug Profiles

CIGB-845 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GM-6 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KTA-832 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

M-610.27 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

M-630 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Inhibit IGF-1 and IGF-2 for Breast Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

REGC-7 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy to Activate BDNF, GDNF, IGF1 and VEGF for Peripheral Nerve Injury and Neuropathic Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

xentuzumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) - Dormant Products

Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) - Discontinued Products

Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) - Product Development Milestones

Featured News & Press Releases

Feb 26, 2018: Genervon Presents Innovative CNS Drug Candidate at 2018 BIO CEO & Investor Conference

Dec 08, 2017: GM604 Is a Multi-Target Regulator That Provides a Novel Treatment Strategy for ALS

Mar 23, 2017: Confidential Data from Genervon ALS Phase 2A Clinical Trial Were Released and Published

Jan 10, 2017: Genervon Releases ALS, PD and AD Disease Associated Gene Lists

Modulated by GM6 and Encourages Researchers to Explore New Discoveries beyond Single Target Drug Development Paradigm

Dec 27, 2016: ALS and Alzheimer's disease bioinformatics reports confirm GM6's role as regulator of disease-relevant pathways

Jun 06, 2016: GENERVON GM604 received EUs orphan drug designation to treat ALS

May 23, 2016: ALS Patients from Around the World Responding Well to Genervons GM604

May 03, 2016: GM604 to Be Granted "Orphan Drug" Status in Europe

Sep 22, 2015: Genervon GM604 Reduced TDP-43 Protein Aggregates and Slowed Down ALS Progression

Jun 29, 2015: Genervon Filed Patent for Using GM604 Modulations of ALS Disease Biomarkers Showing Homeostasis, Leading to Prognosis and Therapeutic Treatment for ALS Disease

Apr 17, 2015: Amyotrophic Lateral Sclerosis Statement; FDA

Jan 08, 2015: Genervon Announces ALS Compassionate Use Results

Oct 19, 2014: Genervon Announces ALS and PD Phase 2a Trial Results

Jun 30, 2014: Genervon Announces Biomarker Data from GAL5-001 Clinical Trial for ALS

Apr 28, 2014: Genervon Successfully Completes its Phase 2a Clinical Trial for ALS

Appendix
Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2020

Number of Products under Development by Therapy Areas, H2 2020

Number of Products under Development by Indication, H2 2020

Number of Products under Development by Companies, H2 2020

Products under Development by Companies, H2 2020

Number of Products under Investigation by Universities/Institutes, H2 2020

Products under Investigation by Universities/Institutes, H2 2020

Number of Products by Stage and Mechanism of Actions, H2 2020

Number of Products by Stage and Route of Administration, H2 2020

Number of Products by Stage and Molecule Type, H2 2020

Pipeline by Boehringer Ingelheim International GmbH, H2 2020

Pipeline by Genervon Biopharmaceuticals LLC, H2 2020

Pipeline by Kriya Therapeutics Inc, H2 2020

Pipeline by Regulaxis SAS, H2 2020

Pipeline by Stem Cell Medicine Ltd, H2 2020

Dormant Products, H2 2020

Dormant Products, H2 2020 (Contd..1), H2 2020

Discontinued Products, H2 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2020

Number of Products under Development by Therapy Areas, H2 2020

Number of Products under Development by Top 10 Indications, H2 2020

Number of Products by Mechanism of Actions, H2 2020

Number of Products by Stage and Mechanism of Actions, H2 2020

Number of Products by Routes of Administration, H2 2020

Number of Products by Stage and Routes of Administration, H2 2020

Number of Products by Molecule Types, H2 2020

Number of Products by Stage and Molecule Types, H2 2020

I would like to order

Product name: Insulin Like Growth Factor I - Pipeline Review, H2 2020

Product link: <https://marketpublishers.com/r/I225D13A94E5EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/I225D13A94E5EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970